Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview.

Nitric oxide (NO) mediates multiple physiological and pathophysiological processes in the cardiovascular system. Pharmacological compounds that release NO have been useful tools for evaluating the pivotal role of NO in cardiovascular physiology and therapeutics. These agents constitute two broad classes of compounds, those that release NO or one of its redox congeners spontaneously and those that require enzymatic metabolism to generate NO. In addition, several commonly used cardiovascular drugs exert their beneficial action, in part, by modulating the NO pathway. Here, we review these classes of agents, summarizing their fundamental chemistry and pharmacology, and provide an overview of their cardiovascular mechanisms of action.

[1]  A. Wear CIRCULATION , 1964, The Lancet.

[2]  JosephLoscalzo Folate and Nitrate-Induced Endothelial Dysfunction , 2001 .

[3]  J. Loscalzo Folate and nitrate-induced endothelial dysfunction: a simple treatment for a complex pathobiology. , 2001, Circulation.

[4]  C. Remacle,et al.  S-nitrosothiols do not induce oxidative stress, contrary to other nitric oxide donors, in cultures of vascular endothelial or smooth muscle cells. , 2001, European journal of pharmacology.

[5]  W. Simmons,et al.  Bradykinin metabolism in the isolated perfused rabbit heart , 2001, Journal of hypertension.

[6]  J. Loscalzo Nitric oxide insufficiency, platelet activation, and arterial thrombosis. , 2001, Circulation research.

[7]  M. Tantucci,et al.  Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat , 2001, Neuroscience Letters.

[8]  C. Napoli,et al.  Nitric oxide and atherosclerosis. , 2001, Nitric oxide : biology and chemistry.

[9]  L. Ignarro,et al.  Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Napoli,et al.  Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  L. Lerman,et al.  Simvastatin Preserves Coronary Endothelial Function in Hypercholesterolemia in the Absence of Lipid Lowering , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[12]  R. Kloner,et al.  Sex and the patient with cardiovascular risk factors: focus on sildenafil. , 2000, The American journal of medicine.

[13]  K. Muraki,et al.  Nifedipine and nisoldipine modulate membrane potential of vascular endothelium via a myo-endothelial pathway. , 2000, Life sciences.

[14]  S. King,et al.  P-Nitrosophosphate compounds: new N-O heterodienophiles and nitroxyl delivery agents. , 2000, The Journal of organic chemistry.

[15]  H. Birnboim,et al.  Depletion of intracellular glutathione reduces mutations by nitric oxide-donating drugs. , 2000, Nitric oxide : biology and chemistry.

[16]  D. Garvey,et al.  Nitrosothiol esters of diclofenac: synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. , 2000, Journal of medicinal chemistry.

[17]  M. Simons Molecular multitasking: statins lead to more arteries, less plaque , 2000, Nature Medicine.

[18]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[19]  K. Takeuchi,et al.  Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats. , 2000, Life sciences.

[20]  D. Webb,et al.  Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. , 2000, Journal of the American College of Cardiology.

[21]  M. Emerson,et al.  Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. , 2000, European journal of pharmacology.

[22]  L. Keefer,et al.  Diazeniumdiolates: pro- and antioxidant applications of the "NONOates". , 2000, Free radical biology & medicine.

[23]  J. Loscalzo What we know and don't know about L-arginine and NO. , 2000, Circulation.

[24]  E. Edelman,et al.  Local drug delivery: an emerging approach in the treatment of restenosis , 2000, Vascular medicine.

[25]  N. Vaziri,et al.  Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. , 2000, The Journal of pharmacology and experimental therapeutics.

[26]  U. Förstermann,et al.  Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. , 2000, Circulation research.

[27]  M. Rand,et al.  Differential actions of L‐cysteine on responses to nitric oxide, nitroxyl anions and EDRF in the rat aorta , 2000, British journal of pharmacology.

[28]  G. Welch,et al.  Nitric Oxide and the Cardiovascular System , 2000, Contemporary Cardiology.

[29]  T. Ogihara,et al.  Pranidipine enhances the action of nitric oxide released from endothelial cells. , 2000, Hypertension.

[30]  C. Napoli,et al.  Nitric oxide as a signaling molecule in the vascular system: an overview. , 1999, Journal of cardiovascular pharmacology.

[31]  J. Viikari,et al.  HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. , 1999, Atherosclerosis.

[32]  J. Leza,et al.  Neuroprotective effects of DETA-NONOate, a nitric oxide donor, on hydrogen peroxide-induced neurotoxicity in cortical neurones , 1999, Neuropharmacology.

[33]  R. Weiss,et al.  Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase. , 1999, Journal of the American Society of Nephrology : JASN.

[34]  W. Linz,et al.  Interactions among ACE, kinins and NO. , 1999, Cardiovascular research.

[35]  G. Kojda,et al.  Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. , 1999, Cardiovascular research.

[36]  R. Sorrentino,et al.  NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. , 1999, Trends in pharmacological sciences.

[37]  D. Garvey,et al.  Design and evaluation of nitrosylated alpha-adrenergic receptor antagonists as potential agents for the treatment of impotence. , 1999, The Journal of pharmacology and experimental therapeutics.

[38]  K. Schönafinger Heterocyclic NO prodrugs. , 1999, Farmaco.

[39]  H. Jo,et al.  Biological aspects of reactive nitrogen species. , 1999, Biochimica et biophysica acta.

[40]  J. Zweier,et al.  Non-enzymatic nitric oxide synthesis in biological systems. , 1999, Biochimica et biophysica acta.

[41]  J. Loscalzo,et al.  The potent platelet inhibitory effects of S-nitrosated albumin coating of artificial surfaces. , 1999, Journal of the American College of Cardiology.

[42]  I. Osterloh,et al.  Overall cardiovascular profile of sildenafil citrate. , 1999, The American journal of cardiology.

[43]  J. Loscalzo,et al.  Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. , 1999, The Journal of clinical investigation.

[44]  J. Wallace,et al.  In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016. , 1999, Thrombosis research.

[45]  P. Vanhoutte,et al.  Endothelial dysfunction: from physiology to therapy. , 1999, Journal of molecular and cellular cardiology.

[46]  A. Kurtz,et al.  Role of nitric oxide in the control of renin secretion. , 1998, American journal of physiology. Renal physiology.

[47]  R. Brilli,et al.  Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury. , 1998, American journal of respiratory and critical care medicine.

[48]  E. Schiffrin Vascular protection with newer antihypertensive agents. , 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[49]  D. Anderson,et al.  Inhibition of NADPH-cytochrome P450 reductase and glyceryl trinitrate biotransformation by diphenyleneiodonium sulfate. , 1998, Biochemical pharmacology.

[50]  P. Vanhoutte Endothelial dysfunction and inhibition of converting enzyme. , 1998, European heart journal.

[51]  D. Wink,et al.  Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. , 1998, Free radical biology & medicine.

[52]  J. Tardif,et al.  Biocompatibility aspects of new stent technology. , 1998, Journal of the American College of Cardiology.

[53]  K. Takeuchi,et al.  Role of Nitric Oxide in Pathogenesis of Aspirin-Induced Gastric Mucosal Damage in Rats , 1998, Digestion.

[54]  M. Moskowitz,et al.  Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  M. Feelisch The use of nitric oxide donors in pharmacological studies , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.

[56]  T. Gupta,et al.  Role of Nitric Oxide , 1998, Digestion.

[57]  A. M. Wheatley,et al.  Intrahepatic Modulation of Portal Pressure and Its Role in Portal Hypertension , 1998, Digestion.

[58]  L. Nelin,et al.  The use of inhaled nitric oxide in a wide variety of clinical problems. , 1998, Pediatric clinics of North America.

[59]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[60]  A. Lechi,et al.  NO‐Aspirins: Antithrombotic Activity of Derivatives of Acetyl Salicylic Acid Releasing Nitric Oxide , 1998 .

[61]  F. Bernini,et al.  Direct vascular effects of HMG-CoA reductase inhibitors. , 1997, Atherosclerosis.

[62]  M. Flather,et al.  Complete and incomplete revascularization in multivessel PTCA: what is the clinical impact? , 1998, European heart journal.

[63]  F. Murad Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? , 1998, Recent progress in hormone research.

[64]  U. Laufs,et al.  Inhibition of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Blocks Hypoxia-mediated Down-regulation of Endothelial Nitric Oxide Synthase* , 1997, The Journal of Biological Chemistry.

[65]  J. Wallace,et al.  Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: role of neutrophils. , 1997, American journal of physiology. Gastrointestinal and liver physiology.

[66]  D. Smith,et al.  Incorporation of nitric oxide-releasing crosslinked polyethyleneimine microspheres into vascular grafts. , 1997, Journal of biomedical materials research.

[67]  D. Garvey,et al.  Nitrosylated bovine serum albumin derivatives as pharmacologically active nitric oxide congeners. , 1997, The Journal of pharmacology and experimental therapeutics.

[68]  L. L. Larina,et al.  Urinary Nitrotyrosine Content as a Marker of Peroxynitrite-induced Tolerance to Organic Nitrates , 1997, Journal of cardiovascular pharmacology and therapeutics.

[69]  P. Bellavite,et al.  The Antiplatelet Effects of a New Nitroderivative of Acetylsalicylic Acid - An In Vitro Study of Inhibition on the Early Phase of Platelet Activation and on TXA2 Production , 1996, Thrombosis and Haemostasis.

[70]  S. Rajagopalan,et al.  Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. , 1996, The Journal of clinical investigation.

[71]  D. Harrison,et al.  Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.

[72]  L. Fontana,et al.  In vitro study of the anti-aggregating activity of two nitroderivatives of acetylsalicylic acid. , 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[73]  K. M. Davies,et al.  Nitric oxide-releasing polymers containing the [N(O)NO]- group. , 1996, Journal of medicinal chemistry.

[74]  K. M. Davies,et al.  "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. , 1996, Methods in enzymology.

[75]  J. Loscalzo,et al.  Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. , 1995, The Journal of clinical investigation.

[76]  P. Minuz,et al.  Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid. , 1995, Thrombosis research.

[77]  J. Ritter,et al.  Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. , 1995, The Journal of pharmacology and experimental therapeutics.

[78]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[79]  C. Cockerell,et al.  Nitric oxide: A physiologic messenger: Lowenstein CJ, Dinerman JL, Snyder SH. Ann Intern Med 1994;120:227–237 , 1995 .

[80]  D. Harrison,et al.  Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. , 1995, The Journal of clinical investigation.

[81]  I. Goldstein,et al.  A heterogeneous population of alpha 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine. , 1995, The Journal of urology.

[82]  J. Wallace,et al.  The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs. , 1994, Trends in pharmacological sciences.

[83]  J. Stamler,et al.  In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. , 1994, The Journal of clinical investigation.

[84]  G. Ford,et al.  Nitric oxide mediated venodilator effects of nebivolol. , 1994, British journal of clinical pharmacology.

[85]  C. Lowenstein,et al.  Nitric Oxide: A Physiologic Messenger , 1994, Annals of Internal Medicine.

[86]  S. Snyder,et al.  Nitric oxide: a physiologic messenger molecule. , 1994, Annual review of biochemistry.

[87]  D. Harrison,et al.  Nitroglycerin metabolism in vascular tissue: role of glutathione S-transferases and relationship between NO. and NO2- formation. , 1993, The Biochemical journal.

[88]  J. Stamler,et al.  Biochemistry of nitric oxide and its redox-activated forms. , 1992, Science.

[89]  L. Ignarro,et al.  Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. , 1992, The New England journal of medicine.

[90]  J. Stamler,et al.  S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[91]  Yuan-sheng Gao,et al.  Nebivolol Induces Endothelium Dependent Relaxatíons of Canine Coronary Arteries , 1991, Journal of cardiovascular pharmacology.

[92]  J. Loscalzo,et al.  The hemodynamic effects of S-nitrosocaptopril in anesthetized dogs. , 1991, The Journal of pharmacology and experimental therapeutics.

[93]  Yuan-sheng Gao,et al.  Nebivolol Induces Endothelium-Dependent Relaxations of Canine Arteries , 1991 .

[94]  H. Fung,et al.  Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. , 1990, The Journal of pharmacology and experimental therapeutics.

[95]  J. Loscalzo,et al.  S-nitrosocaptopril. I. Molecular characterization and effects on the vasculature and on platelets. , 1989, The Journal of pharmacology and experimental therapeutics.

[96]  F. Murad,et al.  Effect of In Vivo Nitroglycerin Therapy on Endothelium‐Dependent and Independent Vascular Relaxation and Cyclic GMP Accumulation in Rat Aorta , 1987, Journal of cardiovascular pharmacology.

[97]  J. Loscalzo,et al.  N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. , 1985, The Journal of clinical investigation.

[98]  L. Ignarro,et al.  Relationship between cyclic guanosine 3':5'-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: effects of methylene blue and methemoglobin. , 1981, The Journal of pharmacology and experimental therapeutics.

[99]  L. Ignarro,et al.  Coronary arterial relaxation and guanylate cyclase activation by cigarette smoke, N'-nitrosonornicotine and nitric oxide. , 1980, The Journal of pharmacology and experimental therapeutics.

[100]  J. Parratt Nitroglycerin--the first one hundred years: new facts about an old drug. , 1979, The Journal of pharmacy and pharmacology.

[101]  James R. Parr Att,et al.  Nitroglycerin—the first one hundred years: new facts about an old drug , 1979 .

[102]  L. Ignarro,et al.  Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. , 1979, Journal of cyclic nucleotide research.

[103]  P. Needleman,et al.  Sulfhydryl requirement for relaxation of vascular smooth muscle. , 1973, The Journal of pharmacology and experimental therapeutics.

[104]  W. Murrell Nitro-Glycerine as a Remedy for Angina Pectoris , 1882, Glasgow Medical Journal.

[105]  T. Brunton ON THE USE OF NITRITE OF AMYL IN ANGINA PECTORIS. , 1867 .